Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

Giant-Cell_Vasculitis.jpg

NEJM: Actemra Effective in Giant Cell Arteritis

On May 22, Genentech received FDA approval for the use of subcutaneous (sc) tocilizumab (TCZ) in patients with giant cell arteritis (GCA) – also known as temporal arteritis.

Read Article
WIR.large_.jpg (keep)

The RheumNow Week in Review – 28 July 2017

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

Read Article
vial.infusion.jpg (keep)

Biosimilar Pricing Wars Have Begun

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Read Article
Lupusfoto.jpg

Increased Pulmonary Embolism Risk in Lupus Patients

Systemic lupus erythematosus (SLE) poses numerous vascular risks, many of which are thought to be autoantibody mediated.

Read Article
big%20sick%20the.jpg

“The Big Sick” Movie Review

It's Monday morning and my first patient is a newly diagnosed rheumatoid. This is his first visit back after starting methotrexate 6 weeks ago. Despite doing great and in remission with only one active joint, he asks, “Are sure this is RA? Or could this be Still’s disease?” Admittedly, this is a weird second-visit question, but I was impressed.  

Read Article
detour.jpg

Baricitinib Derailed by FDA Review

Eli Lilly and Co disclosed today that upon further discussions with the US Food and Drug Administration (FDA) there would be a delay in further regulatory decisions regarding baricitinib, a JAK inhibitor, that is being developed for use in rheumatoid arthritis (RA).  

Read Article
pen%20injector.jpg

Benlysta FDA Approved for Sub-Q Use in Lupus

The US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for use in active, autoantibody‑positive Systemic Lupus Erythematosus (SLE) patients.

Read Article
HIV.virus_.jpg

Inflammatory and Autoimmune Diseases are Not Rare in HIV Patients

HIV infection and AIDs has been associated with numerous complications, presumably resulting from impaired immunity from infection.  Sporadic cases and small cohorts of patients with rheumatic and autoimmune syndromes have been described but epidemiology data on the prevalence is scarce.

Read Article

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

Read Article
pregnant_0.jpg

Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too

A population-based claim study from Sweden has shown that lupus and pre-lupus patients are at risk for adverse maternal and fetal outcomes.   

Read Article
×